MISSISSAUGA, ON, June 17, 2021 /CNW/ - Sanofi Canada announced today that a new 300 mg single-dose (single-use) pre-filled pen for DUPIXENT ® (dupilumab injection) is now available in Canada. The ...

Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent 300 mg pre-filled pen expected to be available third quarter of 2020 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has expanded approval of the single-dose Dupixent pre-filled pen for use in children aged as young as 2 ...

The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment. The Food and Drug Administration has approved ...

Please provide your email address to receive an email when new articles are posted on . The Dupixent prefilled pen has been approved by the FDA for all Dupixent indications in patients aged 12 years ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

Dupixent is a branded injectable medication doctors prescribe to treat eosinophilic esophagitis (EoE). Doctors usually prescribe 300 milligrams once per week. They mostly prescribe it to adults, but ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

If approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication TARRYTOWN, N.Y. and PARIS, Nov. 07, 2025 (GLOBE NEWSWIRE) - ...

300 mg pre-filled pen expected to be available third quarter of 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...

This approval was based on findings from two clinical studies conducted in adult patients already receiving maximal standard-of-care inhaled therapy. The BOREAS and NOTUS studies showed a 30% and 34% ...